Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
